Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
about
Vaccinating Italian infants with a new multicomponent vaccine (Bexsero®) against meningococcal B disease: A cost-effectiveness analysisMeningococcal B Vaccination (4CMenB) in Infants and ToddlersHealth and economic outcomes of introducing the new MenB vaccine (Bexsero) into the Italian routine infant immunisation programmeModelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in EnglandAcceptability of meningococcal serogroup B vaccine among parents and health care workers in Italy: a survey.Routine vaccination against MenB: considerations for implementationRe-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study.Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.Meningococcal serogroup A, C, W₁₃₅ and Y conjugated vaccine: a cost-effectiveness analysis in the NetherlandsNew versus old meningococcal group B vaccines: how the new ones may benefit infants & toddlers.Vaccine profile of 4CMenB: a four-component Neisseria meningitidis serogroup B vaccine.Neisseria meningitidis B vaccines: recent advances and possible immunization policies.The next chapter for group B meningococcal vaccines.Immunomics: a 21st century approach to vaccine development for complex pathogens.Need for Optimisation of Immunisation Strategies Targeting Invasive Meningococcal Disease in the Netherlands.Cost-utility analysis of a nationwide vaccination programme against serogroup B meningococcal disease in Israel.The capsular group B meningococcal vaccine, 4CMenB : clinical experience and potential efficacy.Disease Burden of Invasive Meningococcal Disease in the Netherlands Between June 1999 and June 2011: A Subjective Role for Serogroup and Clonal Complex.Vaccine evaluation: lessons from a meningococcal B vaccine.
P2860
Q26779489-689B42F7-B0AD-4498-98CF-726B4C2DACBAQ26782285-0D2B7122-EB5B-48E8-825B-9FF0E21BD936Q28391723-E6B94541-3E30-4662-8E4F-EBA937BBC58BQ33639988-F395D104-20CB-4DCA-A2E4-FEFE002B3030Q33723468-B7B81092-068C-4F4E-9CCB-12A0E1EEA5CFQ34290793-5B766A49-032F-469C-AF15-2560A17A0070Q34316082-B26BB641-049B-4D12-96FC-1DF20D5E3207Q35887617-C1453630-EA99-409A-BC3F-D5D35D55E3A4Q36891586-7A0CA255-DDD8-4669-BC02-65D4554B9545Q37690815-909E913D-1BD1-4316-A60D-36E42834F804Q38176077-C7974695-6674-4E37-9B70-F37BF371EC63Q38183156-E0086867-06D6-4D3D-9492-6BA9ADF3B7F9Q38677309-FC3148C9-BB3A-4DCC-8F1B-A28BD0F09C13Q38728603-1E3E1144-EC38-457B-BC7D-8F57165EEE01Q38931495-66C8CE22-2743-4AFC-B0EB-C616EC419160Q39829514-C72432FE-83A8-46E8-97A1-780EF34B5BD3Q40179042-B35183A5-A826-457D-9401-60BA59A5C9A8Q40783765-77466F6E-9EE5-445F-84AF-F508346CF337Q41491233-711A36AE-23C5-4545-BA91-7C8BD52BB790
P2860
Cost-effectiveness of vaccination against meningococcal B among Dutch infants: Crucial impact of changes in incidence.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 February 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cost-effectiveness of vaccinat ...... mpact of changes in incidence.
@en
Cost-effectiveness of vaccinat ...... mpact of changes in incidence.
@nl
type
label
Cost-effectiveness of vaccinat ...... mpact of changes in incidence.
@en
Cost-effectiveness of vaccinat ...... mpact of changes in incidence.
@nl
prefLabel
Cost-effectiveness of vaccinat ...... mpact of changes in incidence.
@en
Cost-effectiveness of vaccinat ...... mpact of changes in incidence.
@nl
P2093
P2860
P356
P1476
Cost-effectiveness of vaccinat ...... impact of changes in incidence
@en
P2093
Arie van der Ende
Germie P J M van den Dobbelsteen
Hannah Christensen
Maarten J Postma
P2860
P304
P356
10.4161/HV.23888
P50
P577
2013-02-13T00:00:00Z